Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ABL1 | P00519 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 8/20 | 0.46 |
| ▸ | TEK | Q02763 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.42 |
| ▸ | TUBB | P07437 | 1/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194492 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2ABL1KDRTEKNPC1 | |
| SCHEMBL2196539 | 0.81 | CHEK2 (0.47) | ABL1KDRTEK | |
| SCHEMBL2190668 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2ABL1KDRTEKNPC1 | |
| SCHEMBL2193901 | 0.80 | BRAF (0.44) | ABL1KDRMTNR1AMTNR1B | |
| SCHEMBL2191687 | 0.80 | ABL1 (0.42) | ABL1KDRTEKMTNR1AMTNR1B | |
| SCHEMBL3510563 | 0.76 | BRAF (0.58) | KDRTEKNPC1RAB9A | |
| SCHEMBL3508259 | 0.75 | KDR (0.60) | KDR | |
| SCHEMBL2192136 | 0.75 | BRAF (0.66) | SMN1; SMN2KDRTEKNPC1RAB9A | |
| SCHEMBL2193032 | 0.73 | KDR (0.57) | KDRTEK | |
| SCHEMBL3104488 | 0.71 | SMN1; SMN2 (0.55) | SMN1; SMN2ABL1KDRTEKNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172245-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172245-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | SMN1; SMN2 4421/4885ABL1 102/4885KDR 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.